Table 4.
Survival | Covariate | HR | 95% CI | P value |
---|---|---|---|---|
Univariable analysis for each covariate in patients with smoldering type | ||||
OS | pSTAT3 (pos. vs neg.) | 0.39 | 0.15‐0.99 | .041 |
OS | Age ≥70 years | 5.44 | 1.94‐15.30 | .001 |
OS | iATL‐PI: high risk (5.79 ≥ 1.51 × log10 (sIL‐2R [U/mL]) | 4.07 | 1.12‐14.80 | .033 |
PFS | pSTAT3 (pos. vs neg.) | 0.34 | 0.13‐0.89 | .027 |
PFS | Age ≥70 years | 4.12 | 0.15‐11.70 | .008 |
PFS | iATL‐PI: high risk (5.79 ≥ 1.51 × log10(sIL2R[U/mL]) | 3.13 | 0.86‐11.50 | .085 |
Multivariable analysis for pSTAT3, age, and iATL‐PI as covariates in patients with smoldering type | ||||
OS | pSTAT3 (pos. vs neg.) | 0.41 | 0.13‐0.98 | .046 |
OS | Age ≥70 years | 2.73 | 1.50‐13.50 | .007 |
OS | iATL‐PI: high risk (5.79 ≥ 1.51 × log10 (sIL‐2R [U/mL]) | 1.37 | 0.77‐10.70 | .170 |
PFS | pSTAT3 (pos. vs neg.) | 0.29 | 0.099‐0.84 | .023 |
PFS | Age ≥70 years | 3.07 | 1.22‐10.90 | .020 |
PFS | iATL‐PI: high risk (5.79 ≥ 1.51 × log10 (sIL‐2R [U/mL]) | 3.65 | 0.77‐12.30 | .110 |
Abbreviations: CI, confidence interval; HR, hazard ratio; iATL‐PI, indolent ATLL prognostic index; neg., negative; OS, overall survival; PFS, progression‐free survival; pos., positive; pSTAT3, phosphorylated STAT3; sIL‐2, serum interleukin‐2.